WRBY

Company Overview — What Does Warby Parker Inc. Do?

Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores, website, and mobile apps. As of March 17, 2022, it had 160 retail stores in the United States and Canada. The company was formerly known as JAND, Inc. and changed its name to Warby Parker Inc. in June 2021. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. Warby Parker Inc. (WRBY) is classified as a mid-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Neil Blumenthal and employs approximately 3,030 people. With a market capitalization of $2.6B, WRBY is one of the notable companies in the Healthcare sector.

Warby Parker Inc. (WRBY) Stock Rating — Reduce (April 2026)

As of April 2026, Warby Parker Inc. receives a Reduce rating with a composite score of 36.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.WRBY ranks #3,789 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Warby Parker Inc. ranks #637 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

WRBY Stock Price and 52-Week Range

Warby Parker Inc. (WRBY) currently trades at $20.82. The stock lost $0.12 (0.6%) in the most recent trading session. The 52-week high for WRBY is $31.00, which means the stock is currently trading -32.8% from its annual peak. The 52-week low is $13.63, putting the stock 52.8% above its annual trough. Recent trading volume was 1.6M shares, reflecting moderate market activity.

Is WRBY Overvalued or Undervalued? — Valuation Analysis

Warby Parker Inc. (WRBY) carries a value factor score of 37/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 736.70x, compared to the Healthcare sector average of 23.63x — a premium of 3018%. The price-to-book ratio stands at 7.06x, versus the sector average of 2.75x. The price-to-sales ratio is 3.04x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, WRBY trades at 217.89x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Warby Parker Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Warby Parker Inc. Profitability — ROE, Margins, and Quality Score

Warby Parker Inc. (WRBY) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 1.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 0.5% versus the sector average of -33.1%.

On a margin basis, Warby Parker Inc. reports gross margins of 54.5%, compared to 71.5% for the sector. The operating margin is -0.7% (sector: -66.1%). Net profit margin stands at 0.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 17.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

WRBY Debt, Balance Sheet, and Financial Health

Warby Parker Inc. has a debt-to-equity ratio of 96.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.35x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $280M.

WRBY has a beta of 1.80, meaning it is more volatile than the broader market — a $10,000 investment in WRBY would be expected to move 79.8% more than the S&P 500 on any given day. The stability factor score for Warby Parker Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Warby Parker Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Warby Parker Inc. reported revenue of $852M and earnings per share (EPS) of $0.01. Net income for the quarter was $4M. Gross margin was 54.5%. Operating income came in at $-5M.

In FY 2025, Warby Parker Inc. reported revenue of $872M and earnings per share (EPS) of $0.01. Net income for the quarter was $2M. Gross margin was 54.0%. Revenue grew 13.0% year-over-year compared to FY 2024. Operating income came in at $-5M.

In Q3 2025, Warby Parker Inc. reported revenue of $222M and earnings per share (EPS) of $0.05. Net income for the quarter was $6M. Gross margin was 54.1%. Revenue grew 15.2% year-over-year compared to Q3 2024. Operating income came in at $4M.

In Q2 2025, Warby Parker Inc. reported revenue of $214M and earnings per share (EPS) of $-0.01. Net income for the quarter was $-2M. Gross margin was 53.0%. Revenue grew 13.9% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, Warby Parker Inc. has demonstrated a growth trajectory, with revenue expanding from $188M to $852M. Investors analyzing WRBY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

WRBY Dividend Yield and Income Analysis

Warby Parker Inc. (WRBY) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

WRBY Momentum and Technical Analysis Profile

Warby Parker Inc. (WRBY) has a momentum factor score of 43/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 26/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 43/100 reflects moderate short selling activity.

WRBY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Warby Parker Inc. (WRBY) ranks #637 out of 838 stocks based on the Blank Capital composite score. This places WRBY in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing WRBY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full WRBY vs S&P 500 (SPY) comparison to assess how Warby Parker Inc. stacks up against the broader market across all factor dimensions.

WRBY Next Earnings Date

No upcoming earnings date has been announced for Warby Parker Inc. (WRBY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy WRBY? — Investment Thesis Summary

The quantitative profile for Warby Parker Inc. suggests caution. The quality score of 32/100 flags below-average profitability. The value score of 37/100 indicates premium valuation. High volatility (stability score 32/100) increases portfolio risk.

In summary, Warby Parker Inc. (WRBY) earns a Reduce rating with a composite score of 36.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on WRBY stock.

Related Resources for WRBY Investors

Explore more research and tools: WRBY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare WRBY head-to-head with peers: WRBY vs AZN, WRBY vs SLGL, WRBY vs VMD.